S. Karger AG

SHERPA: Unknown

People

  1. Abou-Alfa
    Abou-Alfa
  2. Janjigian
    Janjigian
  3. O'Reilly
    O'Reilly
  4. Ilson
    Ilson
  5. Saltz
    Saltz
  6. Cercek Hanjis
    Cercek Hanjis
  7. Molena
    Molena
  8. Raj
    Raj
  9. Bajorin
    Bajorin
  10. Bodei
    Bodei

Groups

  1. Department of Medicine (57)
  2. Gastrointestinal Oncology Service (57)
  3. Solid Tumor Oncology Division (57)
  4. Center for Pancreatic Cancer Research (15)
  5. Survivorship Research (5)
  6. Surgery (4)
  7. Weinberg Fellows (4)
  8. Graduate Medical Education (3)
  9. Biostatistics Service (2)
  10. Body Imaging Service (2)
Search Within
  1. "Gastrointestinal Oncology Service"
Formats
  1. Meeting Abstract (48)
  2. Journal Article (9)
Groups
  1. Department of Medicine (57)
  2. Gastrointestinal Oncology Service (57)
  3. Solid Tumor Oncology Division (57)
  4. Center for Pancreatic Cancer Research (15)
  5. Survivorship Research (5)
  6. Surgery (4)

More Groups

People
  1. Ghassan Abou-Alfa (18)
  2. Yelena Janjigian (12)
  3. Eileen O'Reilly (8)
  4. David Ilson (4)
  5. Diane Reidy (4)
  6. Andrea Cercek Hanjis (3)

More People

Years
  1. 2024 (7)
  2. 2023 (8)
  3. 2022 (6)
  4. 2021 (5)
  5. 2020 (10)
  6. 2019 (7)

More Years

Publications
  1. Oncology Research and Treatment (46)
  2. Neuroendocrinology (4)
  3. Oncology (4)
  4. Onkologie (2)
  5. Case Reports in Oncology (1)

Results (57)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and efficacy of 12 mg/d lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma (uHCC) and bodyweight (bw) >80 kg in REFLECT
    Meeting Abstract

    Vogel, A.; Kudo, M.; Cheng, A. L.; Sung, M. W.; Finn, R. S.; Lin, A. Y.; Abou-Alfa, G. K.; Alsina, A.; Breder, V.; Tebbutt, N.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Integrated population pharmacokinetic (PopPK) modeling of cabozantinib (C) in patients (pts) with various cancer types including advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Geißler, M.; Nguyen, L. T.; Chapel, S.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Kelley, R. K.; Abou-Alfa, G. K.; Lacy, S.
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Temozolomide in grade 3 neuroendocrine neoplasms (G3 NENs): A multicentre retrospective review
    Meeting Abstract

    Chan, D.; Chan, J.; Halfdanarson, T.; Kunz, P.; McGarrah, P.; Raj, N.; Reidy-Lagunes, D.; Thawer, A.; Whitman, J.; Wu, Y. L.; more...
    Neuroendocrinology (2019)

    Fulltext@MSK | Save
  • Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Waidmann, O.; Merle, P.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Harris, W. P.; Nemunaitis, J.; Olteanu, S.; Sarker, D.; Tan, B. R.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
    Meeting Abstract

    Haag, G. M.; Chen, L. T.; Kang, Y. K.; Satoh, T.; Kato, K.; Chung, H. C.; Kang, W. K.; Chao, Y.; Chen, J. S.; Ott, P. A.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Venerito, M.; Kelley, R. K.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Bolondi, L.; Chan, S. L.; Lim, H. Y.; Baron, A.; Parnis, F.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial
    Meeting Abstract

    Waidmann, O.; Abou-Alfa, G. K.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Merle, P.; Chen, Y. H.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Venerito, M.; Rimassa, L.; Cicin, I.; Blanc, J. F.; Klümpen, H. J.; Zagonel, V.; Tran, A.; Kim, S.; Lin, Z. Z.; Tam, V. C.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Lanreotide autogel/depot (LAN) in lung neuroendocrine tumours (NETs): The randomized, double-blind, placebo (PBO)-controlled, international phase 3 SPINET study
    Meeting Abstract

    Reidy-Lagunes, D.; Kulke, M. H.; Wolin, E. M.; Singh, S.; Ferone, D.; Hörsch, D.; Mirakhur, B.; Hoffmanns, P.; Houchard, A.; Caplin, M.; more...
    Neuroendocrinology (2017)

    Fulltext@MSK | Save
  • Nivolumab ± ipilimumab in patients (pts) with advanced (adv) / metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study
    Meeting Abstract

    Jaeger, D.; Janjigian, Y. Y.; Ott, P. A.; Calvo, E.; Kim, J. W.; Ascierto, P. A.; Sharma, P.; Peltola, K.; Evans, J.; de Braud, F.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save